Hybrid trials using DCT technology and processes; focus on patients and the sites

Highlighting the complexity that Hybrid/DCT brings whilst moving away from the common brick-and-mortar sites.
Discussing the rise in regulator concerns in areas such as investigator oversight, and participant’s safety when face to face contact is limited.
How we tend to focus too much on technology when it’s actually the processes for the patients and the sites that matter even more.
Major points to consider in designing hybrid/DCT trials; building blocks and practical examples to best prepare you to meet the needs of regulators whilst keeping the patient and sites front of mind